United Imaging adds motion to MR
United Imaging was right alongside Philips, Siemens, and GE with the largest exhibitor footprints at the 2024 meeting.

Among the company's most intriguing product unveilings was the uMR Ultra, a 3T MR system designed to visualize body movement during scans to yield clinical insights beyond traditional static imaging. With high-gradient performance (100mT/m at 200T/m/s) and an AI-enabled uAIFI.LIVE platform, the uMR Ultra positions MR as a tool for "videography" rather than just "photography."
The scanner — which is not yet FDA approved — boasts 192 receive channels, and up to 96-channel coil capabilities.

Alongside United Imaging's other unique scanners, (such as its total body PET/CT and 5T MR) it's clear that the relative newcomer to advanced imaging manufacturing is determined to forge its own path in the market.

Mindray announces foray into North American DR market
In addition to unveiling its Resona I8 ultrasound system, Mindray announced plans at RSNA to enter the North American digital radiography (DR) market, with fixed and mobile offerings on the horizon.

Mindray has been manufacturing medical technologies for over 30 years, but the company's U.S. focus has been on patient monitoring, anesthesia, and ultrasound solutions. The company's forthcoming entrance into the DR market will further solidify its place in radiology, (and future RSNA meetings).

In international markets, Mindray has had a presence in DR for many years, with systems like the MobiEye 700 mobile radiography unit and the DigiEye 350 floor-mounted DR system.

GE HealthCare fully acquires Nihon Medi-Physics
As molecular imaging continues to gain momentum, GE HealthCare announced at RSNA that it would be acquiring the remaining 50% of Nihon Medi-Physics (NMP), a radiopharmaceutical company previously co-owned with Sumitomo Chemical.

NMP specializes in agents for SPECT and PET imaging, with products addressing neurology, cardiology, and oncology. Its offerings include VIZAMYL for Alzheimer’s-related imaging, DaTSCAN for Parkinson’s disease and dementia with Lewy bodies, and MYOVIEW for myocardial perfusion imaging. In 2023, the company generated approximately $183 million (¥28.2 billion) in revenue and operates 13 manufacturing facilities.

The transaction is expected to close in early 2025, pending regulatory approval.

U.S. Healthcare Homepage